de Filippis, R. and Al Foysal, A. (2024) Case Report: The Role of Monoamine Oxidase Inhibitors in Treating Resistant Depression. Open Access Library Journal, 11, 1-12. doi: 10.4236/oalib.1112369 .

FDA supports CaaMTech's CT-4201 psilocin program for depression, advancing psychedelic therapy and clearing key regulatory ...

Cybin launches Phase 3 trials for CYB003, aiming to offer lasting relief for Major Depressive Disorder. Backed by promising ...

Vancouver, British Columbia--(Newsfile Corp. - November 12, 2024) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or ...

Mental health treatment ... with depression. No Medication Required: Unlike traditional treatments, TMS does not require ...

Global Central Nervous System Therapeutics Market is valued at approximately USD 143.95 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.5% over the forecast period ...

Both major depressive disorder in remission (rMDD) and mild cognitive impairment (MCI ... shown to be at double the risk of ...

MindMed is poised for significant developments with MM-120 in upcoming trials. Discover why monitoring MNMD stock is ...

Analyst Thomas Shrader of BTIG maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), reducing the price target to $12.00.

Copyright 2024 The Associated Press. All Rights Reserved. People prone to seasonal affective disorder, also known as seasonal depression, are bracing themselves as ...

For those of us with bipolar disorder, the stretch from ... lead to our thoughts and moods spiraling. Both depression and mania can be exacerbated by stress triggers, and the holidays can turn what ...

The objectives of Multifamily Therapy in the management of Difficult-to-Treat Depression should focus ... MFT aims to improve patient adherence to treatment plans, thereby increasing the overall ...